Welcome to ACR Convergence 2022! Today, Dr. Vicki Shanmugam (host of ACR Journals on Air) joins Jon to tackle three, pivotal trials, that will be presented at our annual meeting this year! Join us as they dive into the objectives, the science behind them and their incredible results. You can find each one of the manuscripts discussed on this episode here:

1. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
2. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
3. Genicular Nerve Block for Pain Management in Patients With Knee Osteoarthritis: A Randomized Placebo-Controlled Trial